Introduction
Neuroendocrine tumors (NETs) are a rare, heterogeneous group of tumors classified according to their site of origin, histology, Ki-67 index, and mitotic count [1] .
Metastatic well-differentiated low and intermediate grade NETs are typically managed with long-acting somatostatin analogues (SSAs) or biological agents (everolimus and sunitinib) [2, 3] . In contrast, patients with grade 3 disease are typically managed with chemotherapy. Small cell lung cancer regimens (such as platinum and etoposide) are typically used, but response rates tend to be significantly lower ranging from 30-50% in patients with Ki67 >55% to 15% where Ki 67 is 20-55% [4] [5] [6] [7] [8] . The NORDIC study in particular identified a subgroup characterized by a Ki-67 <55% that had a very low objective response rate to C/E chemotherapy but, nevertheless, a better prognosis than those with a Ki-67 >55%. This and other data support the concept of a group of welldifferentiated G3 NET they may have more in common with G1-2 NET than with G3 NEC [9, 10] .
The role of cytotoxic chemotherapy for patients with welldifferentiated intermediate to high grade NETs has evolved 2 Journal of Oncology over time, though the ideal regimen remains uncertain. Consensus guidelines from the European Neuroendocrine Tumor Society (ENETS) and North American Neuroendocrine Society (NANETS) do not include specific recommendations for a particular chemotherapy regimen. Historically, streptozocin (STZ) regimens (STZ ± doxorubicin or 5-fluorouracil) were the only approved regimens for patients with metastatic pancreatic NETs (pNETs) [11] [12] [13] . Response rates in retrospective studies ranged from 6 to16% with substantial grade 3 and 4 toxicities [14, 15] . More recent studies have examined other chemotherapy regimens, potentially with less toxicity. Retrospective studies have demonstrated efficacy for temozolomide (with or without capecitabine) [16] [17] [18] [19] [20] [21] [22] , oxaliplatin (FOLFOX) [23] , and irinotecan (FOLFIRI) [24] with response rates ranging between 20 and 35%.
Capecitabine and temozolomide (CAPTEM) has demonstrated significant activity in patients with metastatic welldifferentiated pancreatic NETs [25, 26] bd orally on days 1-14 and temozolomide 100 mg/m 2 bd orally on days 10-14 on a 28 day cycle as per standard schedule with premdications and antiemetics [28] . All patients received dexamethasone 8mg and 5HT 3 antagonist on day 10-day 16. Treatment was commenced with neutrophil count > 1.5 and platelet count > 100 and recovery from prior toxicity to grade 1. Dose reductions were done by 20% if febrile neutropenia or significant grade 4 or grade 3 nonhematologic toxicity as per standard protocol [18, 28] .
. . Assessments. The primary endpoints of the study were progression-free survival (PFS) (defined as the time from the date of initiation of CAPTEM to the date of first evidence of progression on FDG PET/CT, which was used as the primary therapeutic response assessment modality) and overall survival (OS) (defined as the time from the date of initiation of CAPTEM to the date of death due to any cause).
The secondary endpoints were response rates on functional imaging, toxicity and the association between extent of prior therapy and functional response. Responses on functional imaging were according to PET response criteria in solid tumors (PERCIST 1.0) [29] .
. . Statistical Analysis. All data was analyzed using SPSS software version 25. Descriptive statistics including median, frequency, and percentage for categorical variables were used to describe age, gender distribution, site of primary, treatment, and response to treatment. Survival analysis was performed using Kaplan-Meier estimates and log-rank test for bivariate comparisons. The collected data for the purpose of the statistical analysis to support the findings of this study are available from the corresponding author upon request.
Results
Thirty-two patients were eligible [male: n=13, female: n=19, and median age at enrolment: 58 (range: 31-76)]. Baseline characteristics are shown in Table 1 . Grade 3 tumors were divided on the basis of Ki67 into low grade 3 (Ki67< 55%) and high grade 3 (Ki67 ≥ 55%). Previous SSA therapy was not considered a line of therapy. The median time from diagnosis until onset of treatment with CAPTEM was 17 months (range: 1-132 months). Median number of cycles received was 6 (range 2-16). MGMT methylation status was not available as it was not routinely evaluated in our patients with NET.
. . Functional Imaging Response. The best functional imaging response achieved was complete metabolic response in four patients (12.5%) while 11 (34.4%) achieved a partial metabolic response and five (15.6%) had stable disease. The overall objective response rate was 46.9% and the objective disease control rate was 62.5%. . . Survival Outcomes. After a median of 31 months of follow-up, the median OS for the entire cohort was 24 months (95% CI: 17.1-30.8) and the two-year OS was 42% (Figure 1 ). The median OS for patients with grade 2 NETs was 24 months versus 19 months for grade 3 NETs (p = 0.42) (Figure 2) .
Patients with low grade 3 (Ki67 20-55%) had a higher OS compared to those with high grade 3 NETs (Ki67 ≥ 55%) (36 versus 17 months, p = 0.169) (Figure 3) , as did patients who received CAPTEM as first-line therapy compared to those who had received prior lines of systemic therapy (29 versus 20 months, p= 0.49). As shown, these differences were not statistically significant. There was no difference in OS with respect to the site of primary (gastroenteropancreatic versus lung) or the site of metastasis.
The median PFS for the entire cohort was 10 months (95% CI: 3.7-16.2) (Figure 4) . The median duration of response was 21 months (95% CI: 8.8-33.1). There was a trend towards an improved median PFS for grade 2 versus grade 3 NET but this was not statistically significant (10 versus 5 months, p= 0.3) ( Figure 5 ). There was also a trend towards improved median PFS in patients with low grade 3 (15 versus 4 months, p = 0.117) and for patients who received CAPTEM as first-line therapy compared to those who had received prior lines of therapy (17 versus 8 months, p= 0.3).
. . Toxicity. The toxicity profile of CAPTEM is shown in Table 2 . Grade 3 and 4 toxicities were seen in 10 patients (31.3%). The most commonly reported grade 3 and 4 toxicities were nausea (15.6%), thrombocytopenia (12.5 %), fatigue (9.4%), anaemia (9.4%), febrile neutropenia (9.4%), diarrhoea (6.3%), vomiting (3.1%), and mucositis (3.1%). Treatment discontinuation due to toxicity occurred in 4 patients (12.5%) (3 for febrile neutropenia and 1 for grade 4 multiple nonhematologic toxicities) while 16 (50%) of patients continued the regimen till progression. None of the patients were continued on a single drug as maintenance.
Discussion
The optimal treatment for patients with metastatic intermediate and high grade NETs is not established. A few retrospective and prospective studies have demonstrated activity of CAPTEM in patients with advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs. There has been considerable difference among the reports with regards to the line of therapy, site of primary (pNET or non-PNET), response evaluation (conventional imaging vs functional imaging), and even dosing schedule of CAPTEM regimen. Although the numbers are small, this study highlights the improved survival with CAPTEM in first line which needs to be further evaluated in a prospective manner. We observed an objective response rate of 46.9% and a disease control rate of 62.5%. The median PFS was 10 months with a 2-year OS of 42%. In an exploratory analysis of patients who received CAPTEM in the first line, we demonstrated a median PFS of 17 months. This is consistent with previously reported data. In a series of 30 patients with metastatic well-or moderatelydifferentiated tumors pancreatic neuroendocrine tumors who received CAPTEM in the first-line setting, the response rate was 70% with a median PFS of 18 months [16] . Similarly, in another retrospective study of patients with metastatic intermediate and high grade NETs (pancreatic and nonpancreatic included) receiving CAPTEM, median PFS was 15.9 months with CAPTEM when used in first line as compared to 3.1 months when used in subsequent lines of therapy [30] .
There is a wide variation in the clinical course and outcomes of patients with Ki-67 values greater than 20%. This is consistent with the results of our study which suggests that patients with Ki 67 20-55% had improved survival outcomes as compared to patients with Ki 67> 55%.
A single prospective phase II study has examined CAPTEM in patients with a variety of metastatic NETs [28] . An interim analysis of 28 out of a planned 38 patients with typical and atypical carcinoids, pituitary, and pancreatic NETs demonstrated an overall response rate of 43% with stable disease in 54%. The median PFS was greater than 20 months and OS greater than 25.3 months. Similarly, the E2211 study in metastatic low and intermediate grade pancreatic NETs demonstrated an improvement in OS. It also reported the longest PFS for any pancreatic NET-directed therapy [31] . This study randomized 144 pretreated patients with metastatic low and intermediate grade pancreatic NETs comparing temozolomide (200 mg/m2 PO QD days 1-5) vs. temozolomide plus capecitabine (T 200 mg/m2 PO QD days 10-14; C 750 mg/m2 PO BID days 1-14. The median PFS for CAPTEM in this study was 22.7 months whereas the median OS was not reached.
CAPTEM appears to be relatively well tolerated, with nausea, thrombocytopenia, and anaemia the most common grade 3 or 4 toxicities. Being a retrospective study, the toxicities might not have been adequately captured so it may not be representative for the chemotherapy regimen. However out results are consistent with previous retrospective reports of CAPTEM toxicity [16, 18, 25] . The median number of cycles delivered in our review was six. The median number of cycles of CAPTEM in earlier studies ranged between 6 and 10 [16, 26, 31] .
The audit has its limitations of being retrospective and of a small sample size as expected of uncommon tumors. Conversely, the selection of patients for treatment on the basis of functional imaging and, specifically, the requirement for sites of disease with FDG-avidity that lack SSTR expression is likely to have biased the population of G3 NEN towards a poorer prognostic group given the adverse outcomes in such patients [32, 33] . It is also difficult to have accurate radiological response data with RECIST evaluation in retrospective studies. However in our study functional imaging has supported the survival parameters and has confirmed that the results of our study are to be in line with other retrospective studies and add to the growing body of evidence for the use of CAPTEM in this rare malignancy.
Conclusion
CAPTEM is an oral chemotherapy regimen which is associated with objectives responses and promising survival outcomes in metastatic well-differentiated intermediate and high grade NETs, including in non-pNET tumors. In particular, survival outcomes in the first-line setting and the low grade 3 (Ki67<55%) subgroup are promising and require further investigation. The toxicity profile of CAPTEM is favorable compared to streptozocin-based regimens and other targeted agents and comparable to other chemotherapy regimens. The ENETs guidelines currently recommend this regimen for patients with intermediate and high grade NETs as a second line therapy [34] . Randomized, prospective trials are needed to further evaluate this regimen, particularly in the subgroups identified, and establish a standard of care in this rare malignancy.
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